PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33635755-14	2020	CBD is hydroxylated to 7-OH-CBD and 7-COOH-CBD by cytochrome P450 enzymes CYP3A4 and CYP2C9 in the liver and is excreted mainly in feces and less in urine.	Cannabidiol	0-3	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	85-91	
21704641-7	2011	Seven of 14 recombinant human CYP enzymes examined (CYP1A1, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) were capable of metabolizing CBD.	Cannabidiol	142-145	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	68-74	
34330718-6	2021	The results from reaction phenotyping experiments with recombinant CYP enzymes and CYP-selective chemical inhibitors indicated that both CYP2C19 and CYP2C9 are capable of CBD metabolism to 7-OH-CBD.	Cannabidiol	171-174	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	149-155	
34330718-9	2021	In a subset of single-donor human liver microsomes with moderate to low CYP2C19 activity, CYP2C9 inhibition significantly reduced 7-OH-CBD formation, suggesting that CYP2C9 may play a greater role in CBD 7-hydroxylation than previously thought.	Cannabidiol	200-203	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	90-96	
34330718-9	2021	In a subset of single-donor human liver microsomes with moderate to low CYP2C19 activity, CYP2C9 inhibition significantly reduced 7-OH-CBD formation, suggesting that CYP2C9 may play a greater role in CBD 7-hydroxylation than previously thought.	Cannabidiol	200-203	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	166-172	
34330718-10	2021	Collectively, these data indicate that both CYP2C19 and CYP2C9 are important contributors in CBD metabolism to the active metabolite 7-OH-CBD.	Cannabidiol	93-96	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	56-62	
34330718-11	2021	Significance Statement This study demonstrates that both CYP2C19 and CYP2C9 are involved in CBD metabolism to the active metabolite 7-OH-CBD, and CYP3A4 is a major contributor to CBD metabolism through pathways other than 7-hydroxylation.	Cannabidiol	92-95	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	69-75	
26267945-4	2015	Cytochromes P450 (CYP) 2C9 and 3A4 are involved in the metabolism of tetrahydrocannabinol and cannabidiol, which implies possible DDI with CYP450 inhibitor and inducer, such as anticonvulsivants and HIV protease inhibitors, which may be prescribed in patients with neuropathic pain.	Cannabidiol	94-105	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-26	
31433338-6	2019	FINDINGS: After comparing the in vitro inhibition parameters to physiologically achievable cannabinoid concentrations, it was concluded that CYP2C9, CYP1A1/2, and CYP1B1 are likely to be inhibited by all 3 major cannabinoids Delta-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN).	Cannabidiol	259-270	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	141-147	
31433338-6	2019	FINDINGS: After comparing the in vitro inhibition parameters to physiologically achievable cannabinoid concentrations, it was concluded that CYP2C9, CYP1A1/2, and CYP1B1 are likely to be inhibited by all 3 major cannabinoids Delta-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN).	Cannabidiol	272-275	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	141-147